Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cytophage Technologies Ltd V.CYTO

Alternate Symbol(s):  CPTCF

Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.


TSXV:CYTO - Post by User

Comment by a2bmanon May 23, 2024 12:21pm
66 Views
Post# 36054144

RE:Avian flu in cows milk

RE:Avian flu in cows milkThe Lancet Infectious Disease journal reported in its review of 59 clinical studies between 2000 and 2021, that of 1,904 patients with chronic and drug resistant infections treated with phages, 79% showed improvement, while 87% of the target bacteria were eradicated in 1,461 of the cases.Jan 3, 2024
<< Previous
Bullboard Posts
Next >>